Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study

Next Previous
X
Search
Trial Profile

HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boceprevir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Telaprevir (Primary) ; Antivirals; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HCV-TARGET

    • Most Recent Events

    • 23 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 24 Jun 2023 Results comparing the safety and efficacy of early vs late HCV treatment initiation in D+/R- non-liver solid organ recipients presented at the European Association for the Study of the Liver Congress 2023
    • 05 Jun 2023 Planned End Date changed from 31 Mar 2023 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top